Levy L, Huszti E, Tikkanen J, et al. - Researchers hypothesized that an untreated first spirometrically-stable A1 rejection (StA1R) does not raise the risk of chronic lung allograft dysfunction (CLAD) or death in comparison with episodes of spirometrically-stable no acute cellular rejection (ACR) (StNAR). No important variation in risk of CLAD or death in patients with a first StA1R vs StNAR was exhibited by the analyses. Thus, an untreated first A1 ACR in the first-year posttransplant was not significantly correlated with an elevated risk for CLAD or death in clinically stable patients. In LT recipients, watchful-waiting approach may be an acceptable way for stable A1 episodes.